ERBB2 and urinary bladder neoplasm: In another retrospective study, seven patients with HER2 overexpressing (IHC 2+ or 3+) NMIBC, who could neither have their bladder tumor completely resected nor tolerate surgery, were treated with either DV or a combination of DV and ICIs, showing promising efficacy and an ORR of 85.7% for all patients (Hu et al., 2023).